- Home
- DYN
as 02-21-2025 12:35pm EST
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.
| Founded: | 1984 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 2.6B | IPO Year: | 2020 |
| Target Price: | $50.78 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.07 - $47.45 | Next Earning Date: | 03-04-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Dyne Therapeutics Inc. (DYN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Scalzo Richard William | DYN | SVP, Head of Finance & Admin. | Feb 18 '25 | Sell | $13.95 | 2,488 | $34,707.60 | 124,590 | |
| Scalzo Richard William | DYN | SVP, Head of Finance & Admin. | Dec 11 '24 | Sell | $28.12 | 1,455 | $40,914.60 | 124,590 | |
| Beskrovnaya Oxana | DYN | Chief Scientific Officer | Dec 11 '24 | Sell | $28.12 | 2,334 | $65,632.08 | 201,685 | |
| Kersten Dirk | DYN | Director | Dec 6 '24 | Sell | $29.26 | 136,112 | $3,988,016.16 | 5,434,982 | |
| Kersten Dirk | DYN | Director | Dec 4 '24 | Sell | $29.22 | 138,845 | $4,079,360.51 | 5,434,982 | |
| Kersten Dirk | DYN | Director | Dec 2 '24 | Sell | $29.69 | 110,933 | $3,273,008.14 | 5,434,982 |
Latest Dyne Therapeutics Inc. News
DYN Breaking Stock News: Dive into DYN Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference
Zacks
8 days ago
After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics (DYN)
Insider Monkey
15 days ago
Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now
GlobeNewswire
18 days ago
Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Zacks
18 days ago
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol
Zacks
21 days ago
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
Zacks
24 days ago
Down -42.2% in 4 Weeks, Here's Why Dyne Therapeutics (DYN) Looks Ripe for a Turnaround
MT Newswires
a month ago
Dyne Therapeutics Says US FDA Grants Fast Track tag to Neuromuscular Disease Therapy
Compare DYN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DYN Dyne Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.